Karin Johnson's questions to Altimmune Inc (ALT) leadership • Q3 2024
Question
Omar, on behalf of Karin Johnson from Goldman Sachs, inquired about the selection criteria for the three new indications and the anticipated size of the first Phase II trial scheduled to begin in the first half of 2025.
Answer
CMO Dr. Scott Harris explained that the indications were chosen based on targets in patients with obesity that would specifically benefit from glucagon's effects. He emphasized these will be Phase II proof-of-concept studies, not Phase I, and that further details on the indications and trial sizes will be provided after regulatory discussions are completed.